James P. Allison

Dr. Allison serves as chair of The University of Texas MD Anderson Cancer Centre Department of Immunology. Dr. Allison has a longstanding interest in the mechanisms of T cell development and activation, the development of novel strategies for tumor immunotherapy. His research led to the development of ipilimumab, which was approved in 2011 by the FDA for the treatment of metastatic melanoma. Most recently, Dr. Allison was awarded the 2018 Nobel Prize in Physiology or Medicine jointly with Dr. Tasuku Honjo for their discovery of cancer therapy by inhibition of negative immune regulation.